302 patents
Page 8 of 16
Utility
PCSK9 inhibitors and methods of use thereof
15 Feb 22
Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
Filed: 16 Jan 20
Utility
MPO inhibitors for use in medicine
15 Feb 22
The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.
Andrew Whittaker, Hitesh Jayantilal Sanganee
Filed: 12 Jul 18
Utility
Amino-triazolopyridine Compounds and Their Use in Treating Cancer
10 Feb 22
Maurice Raymond Verschoyle FINLAY, Frederick Woolf GOLDBERG, Attilla Kuan Tsuei TING
Filed: 27 Aug 21
Utility
AZD0328 Dosage Regime for Treating Cognitive Impairment
10 Feb 22
The nicotinic acetylcholine receptor alpha 7 (□7 nAChR) agonist ((3R)-Spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of mild cognitive impairment (MCI) in Parkinson's disease, wherein the compound is administered in a unit dose of from 0.25 mg to 0.50 mg twice daily.
DAVID JOHN HAYES
Filed: 23 Sep 19
Utility
Methods of Delaying Pain Progression and Treating Prostate Cancer
10 Feb 22
This disclosure relates to methods for delaying pain progression in a subject receiving treatment for prostate cancer.
JINYU KANG
Filed: 3 Aug 21
Utility
Protein kinase B inhibitors
1 Feb 22
Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
Filed: 7 Apr 20
Utility
Methods of Treating Chronic Kidney Disease with Dapagliflozin
27 Jan 22
The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Anna Maria LANGKILDE
Filed: 1 Apr 21
Utility
Combination of Zibotentan and Dapagliflozin for the Treatment of Endothelin Related Diseases
27 Jan 22
The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
Peter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES
Filed: 9 Jul 21
Utility
Methods of Treating Chronic Kidney Disease with Dapagliflozin
27 Jan 22
The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
Anna Maria LANGKILDE
Filed: 14 Jun 21
Utility
Methods of Treating Cancer
13 Jan 22
Methods of treating Mcl-1 dependent cancers are described herein.
Justin CIDADO, Scott BOIKO, Lisa DREW
Filed: 13 Nov 19
Utility
Chemical Compounds
13 Jan 22
JEFFREY WALLACE JOHANNES, SUDHIR MAHADEO HANDE, AVIPSA GHOSH, XIAOLAN ZHENG, MARTIN PACKER, SEBASTIEN LOUIS DEGORCE
Filed: 22 Jun 21
Utility
Combination Therapy for Treating Cancer
16 Dec 21
Disclosed are methods of treating cancer comprising administering to a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of AZD2811 nanoparticles and venetoclax.
Wolfram BRUGGER
Filed: 26 Jul 19
Utility
Classification of Immuno-Oncology Impact
16 Dec 21
An embodiment may involve reading conditions for respectively determining research impacts of cancer-related journal publications, congress activities, guideline activities, and trial activities; reading data regarding the cancer-related journal publications, the congress activities, the guideline activities, and the trial activities of each of a plurality of individuals; applying the conditions to the data on a per-individual basis to determine partial grades and overall grades for each of the plurality of individuals, wherein applying the conditions to the data of a particular individual involves: determining individual partial grades respectively for the cancer-related journal publications, the congress activities, the guideline activities, and the trial activities of the particular individual, and determining an individual overall grade for the particular individual based on a sum of the individual partial grades; and storing the overall grades and the partial grades for each of the plurality of individuals.
Nicole Denise St. Jean, Craig Russell Maxwell, Elizabeth Maybelle Shaheen-Dumke, Evangelos Pazarentzos, Sesquile Ramon
Filed: 2 Jun 21
Utility
2,3-DIHYDROISOINDOLE-1-CARBOXAMIDES Useful As Ror-gamma Modulators
9 Dec 21
Sarah LEVER, Frank NARJES, Roine Ingemar OLSSON, Stefan VON BERG
Filed: 7 May 21
Utility
Methods for Treating Severe Asthma In Patients with Nasal Polyposis
9 Dec 21
Provided herein are methods of reducing exacerbations of asthma in an asthma patient with nasal polyposis, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
Maria Esther GARCIA GIL, James ZANGRILLI, Anne Burden, James KREINDLER
Filed: 4 Jun 21
Utility
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
2 Dec 21
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).
Yuri RUKAZENKOV, Serban GHIORGHIU, Flavia BORELLINI, Helen MANN
Filed: 25 May 21
Utility
PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDE
2 Dec 21
The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.
Håkan WIKSTRÖM, Jufang Wu LUDVIGSSON, Thomas ANDERSSON
Filed: 1 Mar 19
Utility
Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof
23 Nov 21
An improved chemical process for the manufacture of the compound of Formula (I), which is useful, for example, as a late-stage chemical intermediate in the production of osimertinib (AZD9291) and pharmaceutically acceptable salts thereof.
Alistair John Boyd, Alexander Telford
Filed: 31 Jan 17
Utility
Pyrazole Derivatives Useful As 5-LIPOXYGENASE Activating Protein (Flap) Inhibitors
18 Nov 21
Johan Olof Broddefalk, Hans Fredrik Emtenäs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
Filed: 22 Apr 21
Utility
Methods and Combinations for the Treatment of Cancer Using Immune Checkpoint Inhibitor Antibodies
18 Nov 21
The disclosure relates to methods, compositions, and combinations for the treatment of cancer.
John Kurland, Alejandra Negro, Shao-Chun Chang
Filed: 12 May 21